BACKGROUND: We sought to determine the current practice patterns of general surgeons in Atlantic Canada in the management of primary rectal cancer in relation to surgeon-specific variables. METHODS: We sent mail-out surveys to all practising general surgeons (n = 183) in Atlantic Canada to determine screening preferences, preoperative assessment, the use of neoadjuvant and adjuvant therapy, surgical therapy for rectal cancer and surgeon demographics. We analyzed the responses using χ(2) tests. RESULTS: The response rate was 98 (54%) after 2 mail-outs; there were 82 (49%) eligible responses. Surgeons in practice for 21 years or more were more likely than those with fewer than 21 years of practice to order preoperative ultrasonography of the liver and were less likely to order preoperative computed tomography. Endorectal ultrasonography was ordered routinely by 23% of surgeons, whereas 71% of surgeons would order it if time and resources were available. Surgeons who were not certified by the Royal College of Physicians and Surgeons of Canada were significantly more likely than those who were certified to use neoadjuvant therapy in all patients with rectal cancer (43% v. 12%; p = 0.031). Surgeons who performed more than 10 rectal cancer surgeries per year were significantly more likely than those who performed 10 or fewer surgeries per year to use neoadjuvant treatment for T3 tumours (94% v. 61%; p = 0.007). Surgeons with medical or radiation oncology services in their communities were significantly more likely than those without such services to recommend neoadjuvant treatment in T3 rectal tumours and rectal tumours with pathologic lymph nodes. CONCLUSION: We found significant variation in the management of rectal cancer depending on surgeon-specific variables. The implications of these differences on the outcomes of patients with rectal cancer are unknown.
BACKGROUND: We sought to determine the current practice patterns of general surgeons in Atlantic Canada in the management of primary rectal cancer in relation to surgeon-specific variables. METHODS: We sent mail-out surveys to all practising general surgeons (n = 183) in Atlantic Canada to determine screening preferences, preoperative assessment, the use of neoadjuvant and adjuvant therapy, surgical therapy for rectal cancer and surgeon demographics. We analyzed the responses using χ(2) tests. RESULTS: The response rate was 98 (54%) after 2 mail-outs; there were 82 (49%) eligible responses. Surgeons in practice for 21 years or more were more likely than those with fewer than 21 years of practice to order preoperative ultrasonography of the liver and were less likely to order preoperative computed tomography. Endorectal ultrasonography was ordered routinely by 23% of surgeons, whereas 71% of surgeons would order it if time and resources were available. Surgeons who were not certified by the Royal College of Physicians and Surgeons of Canada were significantly more likely than those who were certified to use neoadjuvant therapy in all patients with rectal cancer (43% v. 12%; p = 0.031). Surgeons who performed more than 10 rectal cancer surgeries per year were significantly more likely than those who performed 10 or fewer surgeries per year to use neoadjuvant treatment for T3 tumours (94% v. 61%; p = 0.007). Surgeons with medical or radiation oncology services in their communities were significantly more likely than those without such services to recommend neoadjuvant treatment in T3 rectal tumours and rectal tumours with pathologic lymph nodes. CONCLUSION: We found significant variation in the management of rectal cancer depending on surgeon-specific variables. The implications of these differences on the outcomes of patients with rectal cancer are unknown.
Authors: Maarten Vermaas; Floris T J Ferenschild; Joost J M E Nuyttens; Andreas W K S Marinelli; Theo Wiggers; Joost R M M van der Sijp; Cornelis Verhoef; Wilfried J Graveland; Alexander M M Eggermont; Johannes H W de Wilt Journal: Dis Colon Rectum Date: 2005-05 Impact factor: 4.585
Authors: K Havenga; W E Enker; J Norstein; Y Moriya; R J Heald; H C van Houwelingen; C J van de Velde Journal: Eur J Surg Oncol Date: 1999-08 Impact factor: 4.424
Authors: Mary E Charlton; Chi Lin; Dingfeng Jiang; Karyn B Stitzenberg; Thorvardur R Halfdanarson; Jane F Pendergast; Elizabeth A Chrischilles; Robert B Wallace Journal: Am J Clin Oncol Date: 2013-12 Impact factor: 2.339
Authors: Marie-Adele S Kress; Naren Ramakrishna; Solomon B Makgoeng; Keith R Unger; Arnold L Potosky Journal: Radiat Oncol Date: 2012-11-08 Impact factor: 3.481